Literature DB >> 16287895

Changes in women's use of hormones after the Women's Health Initiative estrogen and progestin trial by race, education, and income.

Feifei Wei1, Diana L Miglioretti, Maureen T Connelly, Susan E Andrade, Katherine M Newton, Cynthia L Hartsfield, K Arnold Chan, Diana S M Buist.   

Abstract

BACKGROUND: We examined the impact of race, education, and household income on changes in rates of discontinuation and initiation of hormone therapy before and after release of the Women's Health Initiative estrogen plus progestin trial results.
METHODS: We conducted an observational cohort study of 221 378 women aged 40-80 years enrolled in five health maintenance organizations to estimate the prevalence and rates of discontinuation and initiation of estrogen plus progestin and estrogen only between September 1, 1999, to June 31, 2002 (baseline), and December 31, 2002 (follow-up). We identified the census block group for each participant by geocoding her 2003 residential address. We categorized women into racial, education, and income groups based on the distribution of these characteristics in her community from year 2000 census data and the distributions of these characteristics within her HMO.
RESULTS: There were significant differences in estrogen plus progestin and estrogen only prevalence by race, education level, and household income, and in estrogen plus progestin initiation by race and education level, but not by household income at follow-up. However, there were no differences by community race, education, or household income in change in the prevalence of either hormone therapy use at follow-up or in the rates of hormone therapy discontinuation or initiation from baseline to follow-up.
CONCLUSIONS: Given the wide spread media attention to the Women's Health Initiative estrogen plus progestin trial results, our findings suggest comparable dissemination of this information across diverse socioeconomic groups.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16287895     DOI: 10.1093/jncimonographs/lgi047

Source DB:  PubMed          Journal:  J Natl Cancer Inst Monogr        ISSN: 1052-6773


  16 in total

1.  Design and baseline characteristics of the soy phytoestrogens as replacement estrogen (SPARE) study--a clinical trial of the effects of soy isoflavones in menopausal women.

Authors:  Silvina Levis; Nancy Strickman-Stein; Daniel R Doerge; Jeffrey Krischer
Journal:  Contemp Clin Trials       Date:  2010-03-15       Impact factor: 2.226

2.  Breast Cancer and Socioeconomic Status in Austria.

Authors:  Ursula Kunze; Gabriela Böhm
Journal:  Breast Care (Basel)       Date:  2009-08-20       Impact factor: 2.860

Review 3.  The role of soy foods in the treatment of menopausal symptoms.

Authors:  Silvina Levis; Marcio L Griebeler
Journal:  J Nutr       Date:  2010-11-03       Impact factor: 4.798

4.  Menopausal hormone therapy trends before versus after 2002: impact of the Women's Health Initiative Study Results.

Authors:  Sybil L Crawford; Carolyn J Crandall; Carol A Derby; Samar R El Khoudary; L Elaine Waetjen; Mary Fischer; Hadine Joffe
Journal:  Menopause       Date:  2018-12-21       Impact factor: 2.953

Review 5.  Postmenopausal hormone therapy is not associated with risk of all-cause dementia and Alzheimer's disease.

Authors:  Jacqueline O'Brien; John W Jackson; Francine Grodstein; Deborah Blacker; Jennifer Weuve
Journal:  Epidemiol Rev       Date:  2013-09-15       Impact factor: 6.222

6.  Socioeconomic disparities in the decline in invasive breast cancer incidence.

Authors:  Brian L Sprague; Amy Trentham-Dietz; Elizabeth S Burnside
Journal:  Breast Cancer Res Treat       Date:  2010-01-20       Impact factor: 4.872

7.  Postmenopausal Female Hormone Use and Estrogen Receptor-Positive and -Negative Breast Cancer in African American Women.

Authors:  Lynn Rosenberg; Traci N Bethea; Emma Viscidi; Chi-Chen Hong; Melissa A Troester; Elisa V Bandera; Christopher A Haiman; Laurence N Kolonel; Andrew F Olshan; Christine B Ambrosone; Julie R Palmer
Journal:  J Natl Cancer Inst       Date:  2015-11-26       Impact factor: 13.506

8.  The decline in breast cancer incidence: real or imaginary?

Authors:  Allison W Kurian; Christina A Clarke; Robert W Carlson
Journal:  Curr Oncol Rep       Date:  2009-01       Impact factor: 5.075

9.  Use of menopausal hormone therapy and risk of ductal and lobular breast cancer among women 55-74 years of age.

Authors:  Christopher I Li; Janet R Daling; Kara L Haugen; Mei Tzu Chen Tang; Peggy L Porter; Kathleen E Malone
Journal:  Breast Cancer Res Treat       Date:  2014-04-20       Impact factor: 4.872

10.  Recent trends in breast cancer incidence in US white women by county-level urban/rural and poverty status.

Authors:  Amelia K Hausauer; Theresa H M Keegan; Ellen T Chang; Sally L Glaser; Holly Howe; Christina A Clarke
Journal:  BMC Med       Date:  2009-06-26       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.